← Association for Accessible Medicines
FDANonrulemakingFDA-2017-D-6209

Assessing User Fees Under the Biosimilar User Fee Amendments of 2017

RIN
—
Last modified
Jan 23, 2020
Comment window
closed 2924d ago
Association for Accessible Medicines filings
1

Activity

Association for Accessible Medicines filed 1 comment on this docket between Jan 16, 2018 and Jan 16, 2018. 0 other organizations filed here. The comment window closed 2924d ago.

What Association for Accessible Medicines filed (1)

Jan 16, 2018· Comment from Association for Accessible Medicines· FDA-2017-D-6209-0003

Comments from the Association for Accessible Medicines (AAM) and the Biosimilars Council on behalf of our member companies, regarding Docket FDA-2017-D-6209: Assessing User Fees Under the Biosimilar User Fee Amendments of 2017.

View on regulations.gov →

Abstract

No abstract recorded.

View on regulations.gov →

Co-filers (0)

See everyone who commented →
Assessing User Fees Under the Biosimilar User Fee Amendments of 2017 (FDA) — Association for Accessible Medicines | OpenPolis